Evaxion A/S, a clinical-stage TechBio company, has announced that it will present new data for its therapeutic vaccine EVX-04 at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition. This event is significant as it showcases the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The presentation will take place in New Orleans, Louisiana, from December 12-15, 2026.

The new data further validate the effectiveness of EVX-04, demonstrating broad patient coverage and the ability to induce specific T-cell responses in humanized mice. This builds on previous findings that highlighted strong T-cell responses and tumor growth inhibition in preclinical models.

Background

Evaxion A/S operates in the biological products sector, specifically focusing on developing AI-powered immunotherapies. The company trades on the Nasdaq under the ticker symbol EVAX. It was formerly known as Evaxion Biotech A/S, having changed its name in October 2020. The company is incorporated in Denmark and is categorized as an emerging growth company.

What the Filing Says

The filing states, "Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting." This indicates a strong commitment to advancing its research and development efforts in the field of cancer immunotherapy.

Impact

This announcement may significantly impact patients suffering from AML, particularly those who are not eligible for intensive chemotherapy or stem cell transplantation. The data presented could influence treatment options available to these patients and potentially reshape the landscape of AML therapies.

What's Next

The filing does not say what happens next.